EGFR and HER3 are members of the human epidermal growth factor receptor (HER) family and are validated therapeutic targets in advanced solid tumors. EGFR overexpression drives tumor progression in ...
12d
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
Pinetree Therapeutics, Inc. ("Pinetree"), a biotechnology company pioneering next-generation targeted protein degradation approaches for cancer and other serious diseases, today announced that ...
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ...
SINGAPORE -- Treatment with the novel antibody-drug conjugate patritumab deruxtecan (HER3-DXd) after progression with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy resulted ...
Antibody-drug conjugates (ADCs) have emerged as the primary solution for patients who have progressed on EGFR inhibitors and ...
Clinical utility of upfront circulating tumor DNA (ctDNA) genotyping to guide first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): A GOZILA substudy. This is an ASCO Meeting ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. There are many assets with many different ...
A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), ...
LAUSANNE, Switzerland & SANTIAGO DE COMPOSTELA, Spain--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s ...
(Barcelona, Spain — September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously ...
The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007 included a safety run-in period and a randomized expansion phase, which enrolled patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results